Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Laura E. Niklason net worth and biography

Laura Niklason Biography and Net Worth

CEO of Humacyte

Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan. Dr. Niklason has been a member of Humacyte’s Board since the Company’s founding.

What is Laura E. Niklason's net worth?: The estimated net worth of Laura E. Niklason is at least $8.03 million as of November 20th, 2024. Dr. Niklason owns 1,730,884 shares of Humacyte stock worth more than $8,031,302 as of December 21st. This net worth evaluation does not reflect any other investments that Dr. Niklason may own. Additionally, Dr. Niklason receives an annual salary of $899,250.00 as CEO at Humacyte. Learn More about Laura E. Niklason's net worth.
How old is Laura E. Niklason?: Dr. Niklason is currently 61 years old. There are 5 older executives and no younger executives at Humacyte. Learn More on Laura E. Niklason's age.
What is Laura E. Niklason's salary?: As the CEO of Humacyte, Inc., Dr. Niklason earns $899,250.00 per year. Learn More on Laura E. Niklason's salary.
How do I contact Laura E. Niklason?: The corporate mailing address for Dr. Niklason and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Laura E. Niklason's contact information.
Has Laura E. Niklason been buying or selling shares of Humacyte?: Within the last three months, Laura E. Niklason has sold $4,751,627.28 of Humacyte stock. Most recently, Laura E. Niklason sold 261,369 shares of the business's stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a transaction totalling $1,150,023.60. Following the completion of the sale, the chief executive officer now directly owns 1,730,884 shares of the company's stock, valued at $7,615,889.60. Learn More on Laura E. Niklason's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, Humacyte insiders bought shares 4 times. They purchased a total of 59,012 shares worth more than $389,301.20. During the last twelve months, insiders at the sold shares 13 times. They sold a total of 4,212,973 shares worth more than $25,940,916.90. The most recent insider tranaction occured on December, 4th when Director Michael T Constantino bought 4,600 shares worth more than $20,194.00. Insiders at Humacyte own 11.2% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 12/4/2024.

Laura E. Niklason Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/20/2024	Sell	261,369	$4.40	$1,150,023.60	1,730,884
11/18/2024	Sell	811,172	$4.44	$3,601,603.68	2,419,712
9/9/2024	Sell	157,704	$5.42	$854,755.68	3,519,558
8/28/2024	Sell	277,090	$6.47	$1,792,772.30	4,029,374
6/11/2024	Sell	358,630	$7.08	$2,539,100.40	4,830,658
6/3/2024	Buy	2,050	$7.37	$15,108.50	238,470
5/31/2024	Sell	809,786	$7.91	$6,405,407.26	5,381,354
9/14/2023	Sell	2,000,000	$2.78	$5,560,000.00	6,191,140
8/21/2023	Sell	602,443	$3.39	$2,042,281.77	8,191,140
8/17/2023	Sell	570,174	$3.68	$2,098,240.32	9,420,562
6/15/2023	Sell	500,000	$3.12	$1,560,000.00	9,990,736
6/13/2023	Sell	4,875,000	$2.60	$12,675,000.00	10,490,736
5/25/2023	Sell	2,625,000	$2.75	$7,218,750.00	15,365,736
12/15/2022	Sell	93,426	$2.63	$245,710.38	18,230,274
12/13/2022	Sell	330,000	$2.84	$937,200.00	18,600,004
9/15/2022	Buy	2,000	$4.14	$8,280.00	1,160,240
5/23/2022	Buy	10,000	$4.83	$48,300.00	1,158,240
12/15/2021	Sell	125,000	$8.88	$1,110,000.00

Laura E. Niklason Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $4.64

$4.45

$6.77

50 Day Range

MA: $4.83

$3.46

$5.82

2 Week Range

Now: $4.64

$2.48

$9.97

Volume

75,231,266 shs

Average Volume

2,735,148 shs

Market Capitalization

$583.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

Laura Niklason Biography and Net Worth

What is Laura E. Niklason's net worth?

How old is Laura E. Niklason?

What is Laura E. Niklason's salary?

How do I contact Laura E. Niklason?

Has Laura E. Niklason been buying or selling shares of Humacyte?

Who are Humacyte's active insiders?

Are insiders buying or selling shares of Humacyte?